CTBO (Cantabio Pharmaceuticals) ROE % Adjusted to Book Value: Negative Equity% (As of Dec. 2018)


What is Cantabio Pharmaceuticals ROE % Adjusted to Book Value?

Cantabio Pharmaceuticals CTBO ROE % Adjusted to Book Value is Negative Equity% as of Dec. 2018.

Cantabio Pharmaceuticals's ROE % for the quarter that ended in Dec. 2018 was Negative Equity. Cantabio Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2018 was N/A. Cantabio Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2018 was Negative Equity.

Cantabio Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Cantabio Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals ROE % Adjusted to Book Value Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 Negative Equity 0.00 0.00 0.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 Negative Equity

CTBO vs TNTY, ETNI, NTRR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Cantabio Pharmaceuticals ROE % Adjusted to Book Value Calculation

Cantabio Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2018 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Cantabio Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2018 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Cantabio Pharmaceuticals (CTBO) has a ROE % Adjusted to Book Value of Negative Equity% as of Dec. 2018. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' ROE % Adjusted to Book Value too high?
Cantabio Pharmaceuticals' current ROE % Adjusted to Book Value is Negative Equity%.
How does Cantabio Pharmaceuticals' ROE % Adjusted to Book Value compare to TNTY and ETNI?
Cantabio Pharmaceuticals' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current ROE % Adjusted to Book Value is Negative Equity% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.